Pediatric Nephrology

, Volume 27, Issue 5, pp 807–812 | Cite as

NGAL distinguishes steroid sensitivity in idiopathic nephrotic syndrome

  • Michael R. Bennett
  • Nuntawan Piyaphanee
  • Kimberly Czech
  • Mark Mitsnefes
  • Prasad Devarajan
Original Article

Abstract

Background

Idiopathic nephrotic syndrome (NS) is the most common glomerular disorder of childhood. Invasive biopsy remains the diagnostic method of choice for NS. Prognosis correlates with steroid responsiveness, from sensitive (SSNS) to resistant (SRNS). Neutrophil gelatinase-associated lipocalin (NGAL) has been demonstrated to be a powerful risk marker of chronic kidney disease progression. We set out to determine if urine NGAL can distinguish between patients with SRNS, SSNS, and healthy controls.

Methods

Urine and clinical data were collected from patients at Cincinnati Children's Hospital who were recently diagnosed with active nephrotic syndrome as well as healthy controls. Participants included SRNS (n = 15), SSNS (n = 14), and healthy controls (n = 10). Urinary NGAL was measured by ELISA and normalized to creatinine.

Results

Median NGAL was significantly (p < 0.001) higher in SRNS (172.3 ng/ml, IQR 18.8–789) than both SSNS (6.3 ng/ml, IQR 4.9–9.9) and healthy controls (6.5 ng/ml, IQR 4.2–9.1). The area under the curve (AUC) for NGAL to distinguish SRNS from SSNS was 0.91 (p < 0.0001). NGAL levels demonstrated a significant negative correlation with glomerular filtration rate (r = −0.5, p < 0.001). Results did not change with NGAL corrected for urine creatinine and were independent of the degree of proteinuria.

Conclusions

NGAL levels differentiate SSNS from SRNS and correlate with disease severity in SRNS.

Keywords

NGAL Nephrotic syndrome FSGS MCD Biomarker 

References

  1. 1.
    Cattran DC, Rao P (1998) Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72–79PubMedCrossRefGoogle Scholar
  2. 2.
    Hari P, Bagga A, Jindal N, Srivastava RN (2001) Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr Nephrol 16:901–905PubMedCrossRefGoogle Scholar
  3. 3.
    Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, Gibson K, Thomas DB (2006) Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol 21:344–349PubMedCrossRefGoogle Scholar
  4. 4.
    Roberti I, Vyas S (2010) Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 25:1117–1124PubMedCrossRefGoogle Scholar
  5. 5.
    Gipson DS, Gibson K, Gipson PE, Watkins S, Moxey-Mims M (2007) Therapeutic approach to FSGS in children. Pediatr Nephrol 22:28–36PubMedCrossRefGoogle Scholar
  6. 6.
    Gulati S, Sharma AP, Sharma RK, Gupta A (1999) Changing trends of histopathology in childhood nephrotic syndrome. Am J Kidney Dis 34:646–650PubMedCrossRefGoogle Scholar
  7. 7.
    Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, Verani R (1999) Changing patterns in the histopathology of idiopathic nephrotic syndrome in children1. Kidney Int 55:1885–1890PubMedCrossRefGoogle Scholar
  8. 8.
    Srivastava T, Simon SD, Alon US (1999) High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 13:13–18PubMedCrossRefGoogle Scholar
  9. 9.
    Smith JM, Stablein DM, Munoz R, Hebert D, McDonald RA (2007) Contributions of the Transplant Registry: The 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant 11:366–373PubMedCrossRefGoogle Scholar
  10. 10.
    Korbet SM (1999) Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 14:68–73PubMedCrossRefGoogle Scholar
  11. 11.
    Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629–639PubMedCrossRefGoogle Scholar
  12. 12.
    Gulati S, Sharma AP, Sharma RK, Gupta A, Gupta RK (2002) Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? Pediatr Nephrol 17:404–408PubMedCrossRefGoogle Scholar
  13. 13.
    Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534–2543PubMedCrossRefGoogle Scholar
  14. 14.
    Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238PubMedCrossRefGoogle Scholar
  15. 15.
    Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, Syed H, Ali S, Barasch J, Devarajan P (2008) Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 3:665–673PubMedCrossRefGoogle Scholar
  16. 16.
    Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A (2009) Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 54:1012–1024PubMedCrossRefGoogle Scholar
  17. 17.
    Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M (2009) Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4:337–344PubMedCrossRefGoogle Scholar
  18. 18.
    Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedCrossRefGoogle Scholar
  19. 19.
    National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1-S266Google Scholar
  20. 20.
    Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR (2009) IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 21:189–197PubMedCrossRefGoogle Scholar
  21. 21.
    Bagshaw SM, Bennett M, Haase M, Haase-Fielitz A, Egi M, Morimatsu H, D'Amico G, Goldsmith D, Devarajan P, Bellomo R (2010) Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med 36:452–461PubMedCrossRefGoogle Scholar
  22. 22.
    Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH 3rd, Ma Q, Dastrala S, Bennett M, Mitsnefes M, Devarajan P (2007) NGAL is an early predictive biomarker of contrast-induced nephropathy in children. PediatrNephrol 22:2089–2095Google Scholar
  23. 23.
    Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Michaluk-Skutnik J (2010) Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol 25:889–897PubMedCrossRefGoogle Scholar
  24. 24.
    Woroniecki RP, Orlova TN, Mendelev N, Shatat IF, Hailpern SM, Kaskel FJ, Goligorsky MS, O'Riordan E (2006) Urinary proteome of steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome of childhood. Am J Nephrol 26:258–267PubMedCrossRefGoogle Scholar
  25. 25.
    Woroniecki RP, Shatat IF, Supe K, Du Z, Kaskel FJ (2008) Urinary cytokines and steroid responsiveness in idiopathic nephrotic syndrome of childhood. Am J Nephrol 28:83–90PubMedCrossRefGoogle Scholar
  26. 26.
    Nishida M, Kawakatsu H, Okumura Y, Hamaoka K (2010) Serum and urinary neutrophil gelatinase-associated lipocalin levels in children with chronic renal diseases. Pediatr Int 52:563–568PubMedCrossRefGoogle Scholar
  27. 27.
    Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N, Buemi M (2008) Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 23:414–416PubMedCrossRefGoogle Scholar
  28. 28.
    Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M (2008) Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res 31:255–258PubMedCrossRefGoogle Scholar
  29. 29.
    Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M (2008) Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res 31:274–279PubMedCrossRefGoogle Scholar
  30. 30.
    Krawczeski CD, Woo JG, Wang Y, Bennett MR, Ma Q, Devarajan P (2011) Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr 158:1009–1115PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  • Michael R. Bennett
    • 1
  • Nuntawan Piyaphanee
    • 1
  • Kimberly Czech
    • 1
  • Mark Mitsnefes
    • 1
  • Prasad Devarajan
    • 1
  1. 1.Division Nephrology and HypertensionCincinnati Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations